Citigroup’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-374,704
| Closed | -$25.4M | – | 7946 |
|
|
2019
Q3 | $25.4M | Buy |
374,704
+251,798
| +205% | +$17.3M | 0.02% | 788 |
|
|
2019
Q2 | $7.15M | Buy |
122,906
+100,534
| +449% | +$5.96M | 0.01% | 1662 |
|
|
2019
Q1 | $1.57M | Sell |
22,372
-72,748
| -76% | -$5.39M | ﹤0.01% | 2924 |
|
|
2018
Q4 | $6.13M | Buy |
95,120
+88,475
| +1,331% | +$6.2M | 0.01% | 1652 |
|
|
2018
Q3 | $466K | Sell |
6,645
-267
| -4% | -$15.6K | ﹤0.01% | 4368 |
|
|
2018
Q2 | $348K | Sell |
6,912
-2,009
| -23% | -$79.7K | ﹤0.01% | 4470 |
|
|
2018
Q1 | $279K | Sell |
8,921
-11,362
| -56% | -$377K | ﹤0.01% | 4597 |
|
|
2017
Q4 | $694K | Buy |
20,283
+5,667
| +39% | +$181K | ﹤0.01% | 3738 |
|
|
2017
Q3 | $469K | Buy |
14,616
+3,150
| +27% | +$99.3K | ﹤0.01% | 4189 |
|
|
2017
Q2 | $373K | Buy |
11,466
+1,948
| +20% | +$61.7K | ﹤0.01% | 4261 |
|
|
2017
Q1 | $299K | Sell |
9,518
-40,000
| -81% | -$1.18M | ﹤0.01% | 4308 |
|
|
2016
Q4 | $1.46M | Buy |
49,518
+38,010
| +330% | +$1.16M | ﹤0.01% | 3296 |
|
|
2016
Q3 | $333K | Buy |
11,508
+2,548
| +28% | +$71K | ﹤0.01% | 4262 |
|
|
2016
Q2 | $232K | Sell |
8,960
-11,291
| -56% | -$300K | ﹤0.01% | 4361 |
|
|
2016
Q1 | $502K | Buy |
20,251
+18,500
| +1,057% | +$508K | ﹤0.01% | 4112 |
|
|
2015
Q4 | $61K | Sell |
1,751
-27,886
| -94% | -$747K | ﹤0.01% | 5774 |
|
|
2015
Q3 | $627K | Buy |
29,637
+22,659
| +325% | +$584K | ﹤0.01% | 3518 |
|
|
2015
Q2 | $193K | Sell |
6,978
-2,369
| -25% | -$66.8K | ﹤0.01% | 4463 |
|
|
2015
Q1 | $285K | Sell |
9,347
-2,716
| -23% | -$86.3K | ﹤0.01% | 4210 |
|
|
2014
Q4 | $385K | Buy |
12,063
+10,508
| +676% | +$342K | ﹤0.01% | 4130 |
|
|
2014
Q3 | $44K | Sell |
1,555
-1,312
| -46% | -$36.6K | ﹤0.01% | 5393 |
|
|
2014
Q2 | $79K | Sell |
2,867
-7,001
| -71% | -$186K | ﹤0.01% | 4855 |
|
|
2014
Q1 | $260K | Sell |
9,868
-1,435
| -13% | -$41.2K | ﹤0.01% | 4085 |
|
|
2013
Q4 | $331K | Sell |
11,303
-887
| -7% | -$28.1K | ﹤0.01% | 4179 |
|
|
2013
Q3 | $373K | Buy |
12,190
+3,965
| +48% | +$133K | ﹤0.01% | 3669 |
|
|
2013
Q2 | $260K | Buy |
+8,225
| New | +$270K | ﹤0.01% | 4057 |
|
Citigroup's GHDX Position: Q4 2019 in Review
Citigroup sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 374,704 shares — an estimated $25.4M sold.
Citigroup first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $25.4M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Citigroup reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Citigroup sold 374,704 Genomic Health, Inc. shares in Q4 2019, an estimated $25.4M.
- Citigroup first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
- Citigroup's Genomic Health, Inc. position peaked at $25.4M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.